21 completed, 4 recruiting, 4 unknown, 2 not yet recruiting. 33 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 21, Recruiting 4, Unknown 4, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD | Phase 2 | Not yet recruiting | Justin Ryder | 40 | 2027-05-01 | 2026-01-20 |
| Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Rutin + Vitamin C, Vitamin C 500mg, Lifestyle Intervention - NAFLD | Phase 2 | Not yet recruiting | Ain Shams University | 120 | 2026-01-01 | 2025-12-30 |
| Digoxin In NASH (CODIN) Digoxin, Placebo - NASH, NAFLD | Phase 2 | Recruiting | Yale University | 144 | 2025-06-05 | 2026-05-26 |
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Efinopegdutide, Placebo - Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 85 | 2024-07-12 | 2026-09-21 |
| A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH DD01, Placebo - NAFLD, NASH | Phase 2 | Completed | Neuraly, Inc. | 67 | 2024-06-13 | 2026-05-01 |
| Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB) Nicotinamide, Placebo - Fatty Liver, Obesity | Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2024-04-23 | 2025-11-18 |
| Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant Semaglutide Pen Injector, Placebo - NAFLD | Phase 2 | Recruiting | University of Virginia | 50 | 2024-02-22 | 2026-06-04 |
| Effect of CoQ10 on the Outcome of MAFLD Patients Coenzyme Q10 Forte® capsules - Fatty Liver, NAFLD | Phase 2 | Recruiting | Ain Shams University | 60 | 2023-10-31 | 2025-03-26 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Efinopegdutide, Semaglutide, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2023-06-23 | 2026-01-12 |
| Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD GH509, Placebo - NASH, NAFLD | Phase 1 / Phase 2 | Unknown | 1Globe Biomedical Co., Ltd. | 180 | 2023-02-28 | 2023-03-28 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-11-04 |
| A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis Rencofilstat, Placebo - Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver | Phase 2 | Unknown | Hepion Pharmaceuticals, Inc. | 120 | 2022-10-15 | 2024-05-03 |
| Ketohexokinase Inhibition in NAFLD Ketohexokinase inhibition, Placebo - NAFLD | Phase 2 | Completed | Maastricht University Medical Center | 15 | 2022-10-01 | 2024-01-24 |
| The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease LUM-201 - NAFLD, Nonalcoholic Fatty Liver | Phase 2 | Completed | Massachusetts General Hospital | 12 | 2022-08-10 | 2026-01-06 |
| Different Doses of ZED1227 vs. Placebo in NAFLD ZED1227, Placebo - NAFLD, Liver Fibrosis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 186 | 2022-04-19 | 2024-05-14 |
| Vigabatrin and Insulin Sensitivity Vigabatrin - NAFLD, Obesity | Phase 2 | Completed | Washington University School of Medicine | 4 | 2021-08-23 | 2025-01-14 |
| Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) Tocotrienols / Vitamin E, Placebo control - Hepatic Steatosis, NAFLD | Phase 2 | Completed | Yuen Kah Hay | 170 | 2021-01-01 | 2024-05-10 |
| Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH MET409 Active, MET409 Placebo, Empagliflozin - NASH, NASH - Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Metacrine, Inc. | 120 | 2020-12-15 | 2021-06-01 |
| Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment Specialized product for medical nutrition (SPP-1), individualized diet - NAFLD, NASH - Nonalcoholic Steatohepatitis | Phase 2 / Phase 3 | Unknown | Russian Academy of Medical Sciences | 45 | 2020-03-20 | 2021-02-03 |
Showing 20 of 33. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (33) · Fatty Liver (9) · Diabetes Mellitus, Type 2 (5) · Liver Cirrhosis (5) · Obesity (4) · Liver Diseases (3) · Diabetes Mellitus (2) · Digestive System Diseases (2) · Insulin Resistance (2) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · HIV Infections (1) · Hyperlipidemias (1) · Hypertriglyceridemia (1) · Inflammation (1)
Digestive System Diseases (31) · Liver Diseases (30) · Fatty Liver (24) · Nutritional and Metabolic Diseases (12) · Pathological Conditions, Signs and Symptoms (10) · Metabolic Diseases (8) · Glucose Metabolism Disorders (6) · Pathologic Processes (6) · Body Weight (5) · Fibrosis (5) · Nutrition Disorders (5) · Overnutrition (5) · Signs and Symptoms (5) · Endocrine System Diseases (4) · Overweight (4)
semaglutide (3) · Diet (2) · Vitamin E (2) · empagliflozin (2) · 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane (1) · Ascorbic Acid (1) · CRV-431 (1) · Control Groups (1) · Dasatinib (1) · Diet, Reducing (1) · Digoxin (1) · Exercise (1) · Glucagon (1) · IONIS-ANGPTL3-LRx (1) · Losartan (1)
Ain Shams University (2) · Merck Sharp & Dohme LLC (2) · 1Globe Biomedical Co., Ltd. (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Adrian Vella (1) · Akcea Therapeutics (1) · Albireo (1) · Dr. Falk Pharma GmbH (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Hepion Pharmaceuticals, Inc. (1) · HighTide Therapeutics (Hong Kong) Limited (1) · Indiana University (1) · Justin Ryder (1) · Karolinska University Hospital (1) · Maastricht University Medical Center (1)
United States (21) · Canada (4) · France (3) · Spain (3) · China (2) · Colombia (2) · Egypt (2) · Israel (2) · Japan (2) · Mexico (2) · Netherlands (2) · Puerto Rico (2) · Thailand (2) · United Kingdom (2) · Australia (1)
Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Adrian Vella (1) · Brandy A Wicklow, MD, MSc (1) · Bubu A Banini, MD, PhD (1) · Dennis To (1) · Deven Parmar, MD FCP (1) · Elif A Oral, MD (1) · Hubert C Chen, MD (1) · Justin Ryder, PhD (1) · Kah Hay Yuen, PhD (1) · Laura E. Dichtel, MD, MHS (1) · Marianne Mancini (1) · Max Nieuwdorp, MD, PhD (1)
PMID 29992039, PMID 30569637, PMID 33898960, PMID 34535644, PMID 35596633, PMID 36318027, PMID 36847136, PMID 40797298, PMID 42014131, PMID 42480572, PMID 42823536, PMID 42844400
2023 (1), R01DK116231 (1), R01DK120612 (1), R01DK134624 (1), R03DK096157 (1)